Dr Waleed Mohammed Consultant oncologist
- Patient age group
- Adults
- Consultant registered on
- 27/07/2010
- Primary medical qualifications
- BA (Cantab), MSc (Oxon), MBBChir (Cantab), MRCP (Lond), FRCR
- Foreign languages
- Gender
- Male
- Services
- Hospitals
Contact
- Phone
- 02033111740
Anne Evans
Background
Dr Mohammed initially trained as a bio-scientist, specializing in genetics at the University of Cambridge and completing an MSc in biology at the University of Oxford, before delving into the pharmaceutical industry (Oxford Science Park and MRC Prion Unit at Queen Square, University College London).
He subsequently re-trained as a medic (Cambridge Graduate Course in Medicine), specializing in clinical oncology, undertaking specialist registrar training at Imperial College NHS Trust, The Royal Marsden Hospital and The Royal Sussex County Hospital. He has been a consultant clinical oncologist at Charing Cross Hospital since 2020, where he introduced, developed and established the SABR radiotherapy service.
He is a member of The Royal College of Physicians (London) and a Fellow of The Royal College of Radiologists (New Fellows Speaker award).
Expertise
Primary and secondary thoracic cancers (NSCLC, SCLC, LCNET, mesothelioma and thymic cancers); primary and secondary CNS (brain and spine) cancers (LGG, HGG, meningioma, ependymoma, medulloblastoma, pituitary tumours, pineal tumours and intra-cranial germ cell tumours).
Research & publications
Early in his career as a geneticist, Dr Mohammed was involved in research elucidating the role of newly discovered genes in development of the early mouse embryo. He was also focused on investigating the biology of lysosomal storage disorders and prion disease in order to develop drug therapy.
As an oncology trainee, he investigated the short-term toxicity of brachytherapy in prostate cancer patients with inflammatory bowel disease, and was awarded first prize for best presentation at international conference level.
As a consultant, he is sub-investigator on a number of clinical trials, and has been focused on service development within the oncology department at Charing Cross Hospital, and most recently established and leads the new SABR radiotherapy service.